METHODS article
Front. Neurosci.
Sec. Neuroscience Methods and Techniques
Volume 19 - 2025 | doi: 10.3389/fnins.2025.1645952
This article is part of the Research TopicBioinformatics tools and approaches for prediction and assessment of protein allergenicity and toxicity potentialView all articles
Key considerations for ELISA-based quantification of diverse amyloid 1 beta forms in murine brain homogenates
Provisionally accepted
- 1Institute of Pharmacy, Uppsala University, Uppsala, Sweden
- 2Uppsala University, Uppsala, Sweden
- 3Department of Public Health and Caring Sciences; Molecular Geriatrics, Uppsala University, Uppsala, Sweden
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Enzyme-Linked Immunosorbent Assay (ELISA) is a widely utilized method for quantifying amyloid beta (Aβ) levels in various biological samples, including brain homogenates. Aβ exist in multiple structural forms: monomers, soluble oligomers, protofibrils, and fibrils, each exhibiting distinct biochemical properties and degrees of neurotoxicity. Their toxic potential also varies by localization, whether intracellular, membrane-bound, or extracellular. Accurate detection and quantification of these diverse Aβ species and localizations are critical for understanding their roles in Alzheimer's disease (AD) pathology. However, suboptimal ELISA configurations and misinterpretations of results can lead to misleading conclusions. This study highlights key considerations for optimizing ELISA protocols specifically for detecting distinct Aβ species and localizations, with a focus on applications in mouse brain tissue. We also provide guidance on antibody selection to improve selectivity and specificity of Aβ detection, ultimately enhancing the reliability and interpretability of ELISA-based Aβ measurements.
Keywords: ELISA-based quantification, Amyloid beta, Alzheimer's disease, antibody, detection, aggregates, oligomers
Received: 12 Jun 2025; Accepted: 09 Sep 2025.
Copyright: © 2025 Metzendorf, Sehlin and Hultqvist. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Nicole G. Metzendorf, Institute of Pharmacy, Uppsala University, Uppsala, Sweden
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.